The majority of FDA and EMA innovator and biosimilar marketed drugs produced by Chinese sites are small However, there are biologics that are being manufactured in China, including Vaxzevria and GlaxoSmithKline’s (Brentford, UK) Xevudy, a monoclonal There are…
Read MoreMoody’s released a report last week discussing the cyber risks associated with the pharmaceutical exposure to systemic and digitization cyber report details the pharmaceutical industry’s systemic risks, labeling them, taken in isolation, as The high-profile nature of…
Read MoreGlobal Migraine Drugs Market In Latin America 2023-2027 The analyst has been monitoring the migraine drugs market in Latin America and it is poised to grow by 31 mn during 2023-2027, accelerating at a CAGR of York,
Read MoreNo Byline Policy Editorial Guidelines Corrections Policy Source
Read MoreThe 26-year-old, Toronto, Canada, native co-founded her first company, Ranomics, at It provides health risk predictions based on people’s genetic data and has now raised more than $1 million, according to She founded her second company, Locke Bio,…
Read MoreGiovanni Caforio, chief executive of the US drugmaker, told the Financial Times it was reviewing its portfolio and expected that some drug candidates would not be funded as a result of reforms in the administration’s Inflation Reduction said cancer…
Read MoreMark Cuban speaking at Life Itself with Sanjay Marc Hodosh No Byline Policy Editorial Guidelines Corrections Policy Source
Read MoreWASHINGTON, Nov 18 (Reuters) – The divided Congress after the November midterm elections undermines pharmaceutical companies who want to weaken a new law that allows the government to negotiate drug prices, Republican strategists, policy experts and pharmaceutical executives
Read MoreDUBLIN–(BUSINESS WIRE)–The “Global Cold Chain Logistics Market for Pharmaceuticals Industry 2023-2027” report has been added to The cold chain logistics market for pharmaceuticals industry is poised to grow by bn during 2023-2027, accelerating at a CAGR of…
Read MoreLONDON/GENEVA, Nov 17 (Reuters) – Pharmaceutical companies could be made to disclose prices and deals agreed for any products they make to fight future global health emergencies, under new rules that would govern a World Health Organization-backed pandemic accord reviewed…
Read More
/cloudfront-us-east-2.images.arcpublishing.com/reuters/PAXEQ6ZYQNKXBHP7D3STCSMIMA.jpg "Analysis: U.S. midterms dampen Big Pharma hopes for drug price policy change")
/cloudfront-us-east-2.images.arcpublishing.com/reuters/SKGIFSIW7ZLKDCT3MBBDJPNHRQ.jpg "Big Pharma may have to reveal government deals in WHO’s draft pandemic rules")